Osteoporosis affects approximately 3.5 million people in the UK, according to the Royal Osteoporosis Society — and women are disproportionately affected. One in two women over 50 will experience an osteoporotic fracture in their remaining lifetime, compared with one in five men. The accelerated bone loss that follows menopause, driven by declining oestrogen levels, makes this fundamentally a women's health issue.

Community pharmacists interact with women at every stage of bone health — from advising younger women on calcium and vitamin D, to counselling post-menopausal patients on bisphosphonate therapy, to identifying risk factors that warrant a GP referral. The renewed Women's Health Strategy emphasises preventive healthcare and early intervention — both central to osteoporosis management.

Understanding the risk

Bone density peaks in the late twenties and declines gradually thereafter. Women lose bone mass at an accelerated rate during the first 5–10 years after menopause, when oestrogen levels fall sharply. By age 70, a woman may have lost 30–40% of her peak bone mass.

Key risk factors pharmacists should be aware of:

Calcium: what pharmacists should recommend

The UK recommended nutrient intake (RNI) for calcium is 700mg daily for adults, though the Royal Osteoporosis Society suggests that women at risk of osteoporosis should aim for 1,000mg daily, ideally from dietary sources.

Dietary sources first:

• A 200ml glass of milk provides approximately 240mg calcium
• A matchbox-sized piece of cheese: 200–300mg
• A 150g pot of yoghurt: 200mg
• Fortified plant milks: variable, typically 120mg per 100ml
• Tinned sardines with bones: 400mg per 100g

Supplements when diet falls short:

• Calcium carbonate (e.g. Calcichew) — cheaper, provides most calcium per tablet, but requires stomach acid for absorption (take with food)
• Calcium citrate — absorbed without stomach acid, better for patients on proton pump inhibitors or with achlorhydria
• Avoid exceeding 1,500mg total daily calcium from all sources — excess calcium does not improve bone health and may carry cardiovascular risks (the evidence is debated but caution is appropriate)

Vitamin D: the essential co-factor

Vitamin D is essential for calcium absorption. Without adequate vitamin D, dietary calcium intake is largely wasted.

UK government guidance recommends 10 micrograms (400 IU) of vitamin D daily for all adults during autumn and winter, and year-round for those with limited sun exposure. The Royal Osteoporosis Society recommends higher doses (800–1,000 IU daily) for people with diagnosed osteoporosis or those at high risk.

Pharmacists should be particularly attentive to:

• Women who cover most of their skin for cultural or religious reasons
• Those who are housebound or work indoors throughout daylight hours
• Women with darker skin (melanin reduces vitamin D synthesis)
• Post-menopausal women not already supplementing

Combined calcium and vitamin D preparations (e.g. Adcal-D3, Calcichew D3) are commonly prescribed alongside bisphosphonates. Pharmacists should check that patients are actually taking them — adherence to "boring" supplements often drops off faster than adherence to the "active" treatment.

Bisphosphonate counselling: where pharmacy makes the biggest difference

Alendronic acid 70mg weekly is the most commonly prescribed first-line treatment for osteoporosis. Adherence is notoriously poor: a 2017 study in Osteoporosis International found that approximately 50% of patients discontinue oral bisphosphonates within the first year.

Pharmacist counselling at first dispensing and during MURs or NMS consultations can significantly improve adherence:

Administration advice (critical for both efficacy and safety):

• Take first thing in the morning on an empty stomach
• Swallow whole with a full glass of plain tap water (not mineral water, tea, coffee or juice — calcium in beverages can chelate the drug)
• Remain upright (sitting or standing) for at least 30 minutes afterwards
• Do not eat, drink anything else, or take other medications for 30 minutes
• Do not lie down after taking — oesophageal irritation risk

Common reasons for non-adherence:

• GI side effects (nausea, oesophageal discomfort) — often related to incorrect administration technique
• Forgetting the weekly dose — suggest linking it to a consistent weekly event
• Not understanding why they need it — patients who have not yet fractured may not perceive risk

Red flags requiring GP referral:

• Persistent heartburn, difficulty swallowing or retrosternal pain after taking alendronate (possible oesophageal ulceration)
• New or unusual thigh or groin pain (rare atypical femoral fractures associated with long-term bisphosphonate use)
• Jaw pain or dental problems (extremely rare osteonecrosis of the jaw — more associated with IV bisphosphonates, but patients should mention bisphosphonate use to their dentist)

Falls prevention: the overlooked pharmacy contribution

Fractures require both weak bones and a fall. Pharmacists reviewing medications can identify drugs that increase fall risk:

• Sedating antihistamines (e.g. chlorphenamine, promethazine)
• Benzodiazepines and Z-drugs
• Antihypertensives causing postural hypotension
• Opioids
• Antidepressants (particularly in the first weeks)

A brief question — "Have you had any falls or near-falls recently?" — during medication reviews can prompt a falls risk assessment referral.

The prevention window

Pharmacists advising younger women — in their twenties and thirties — can emphasise that bone health is built early:

• Weight-bearing exercise (walking, running, dancing, resistance training) during peak bone-building years has lasting benefits
• Adequate calcium and vitamin D throughout life
• Avoiding smoking and excessive alcohol
• Maintaining a healthy body weight

The Women's Health Strategy emphasises prevention as well as treatment. For osteoporosis, the pharmacy conversation at age 30 may be as important as the bisphosphonate dispensing at age 65.

With over 13,000 pharmacies across England and 1,742 active vacancies, the community pharmacy workforce delivers bone health advice at a scale no other healthcare setting can match.

Sources

• Royal Osteoporosis Society: patient and healthcare professional resources
• NICE Technology Appraisal TA464: Bisphosphonates for treating osteoporosis
• NICE Clinical Knowledge Summary: Osteoporosis — prevention of fragility fractures
• SACN vitamin D recommendations (2016)
• Department of Health and Social Care, Women's Health Strategy renewal (April 2026)
• PharmSee pharmacy and vacancy data, accessed April 2026

Find local pharmacy services at PharmSee Pharmacies and explore career data at PharmSee Salary Guide.